Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries
- PMID: 19357785
- PMCID: PMC2664470
- DOI: 10.1371/journal.pone.0005122
Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries
Abstract
Targeting viral vectors to certain tissues in vivo has been a major challenge in gene therapy. Cell type-directed vector capsids can be selected from random peptide libraries displayed on viral capsids in vitro but so far this system could not easily be translated to in vivo applications. Using a novel, PCR-based amplification protocol for peptide libraries displayed on adeno-associated virus (AAV), we selected vectors for optimized transduction of primary tumor cells in vitro. However, these vectors were not suitable for transduction of the same target cells under in vivo conditions. We therefore performed selections of AAV peptide libraries in vivo in living animals after intravenous administration using tumor and lung tissue as prototype targets. Analysis of peptide sequences of AAV clones after several rounds of selection yielded distinct sequence motifs for both tissues. The selected clones indeed conferred gene expression in the target tissue while gene expression was undetectable in animals injected with control vectors. However, all of the vectors selected for tumor transduction also transduced heart tissue and the vectors selected for lung transduction also transduced a number of other tissues, particularly and invariably the heart. This suggests that modification of the heparin binding motif by target-binding peptide insertion is necessary but not sufficient to achieve tissue-specific transgene expression. While the approach presented here does not yield vectors whose expression is confined to one target tissue, it is a useful tool for in vivo tissue transduction when expression in tissues other than the primary target is uncritical.
Conflict of interest statement
Figures
Similar articles
-
Heparan Sulfate Binding Promotes Accumulation of Intravitreally Delivered Adeno-associated Viral Vectors at the Retina for Enhanced Transduction but Weakly Influences Tropism.J Virol. 2016 Oct 14;90(21):9878-9888. doi: 10.1128/JVI.01568-16. Print 2016 Nov 1. J Virol. 2016. PMID: 27558418 Free PMC article.
-
Impact of capsid modifications by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction.J Gen Virol. 2012 Oct;93(Pt 10):2131-2141. doi: 10.1099/vir.0.044735-0. Epub 2012 Jul 4. J Gen Virol. 2012. PMID: 22764318
-
How to Successfully Screen Random Adeno-Associated Virus Display Peptide Libraries In Vivo.Hum Gene Ther Methods. 2017 Jun;28(3):109-123. doi: 10.1089/hgtb.2016.177. Epub 2017 Feb 13. Hum Gene Ther Methods. 2017. PMID: 28193101
-
Adeno-associated viral vectors and their redirection to cell-type specific receptors.Adv Genet. 2009;67:29-60. doi: 10.1016/S0065-2660(09)67002-4. Adv Genet. 2009. PMID: 19914449 Review.
-
Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy.Curr Pharm Des. 2015;21(22):3248-56. doi: 10.2174/1381612821666150531171653. Curr Pharm Des. 2015. PMID: 26027561 Review.
Cited by
-
Adeno-associated virus-based gene therapy treats inflammatory kidney disease in mice.J Clin Invest. 2024 Aug 15;134(17):e174722. doi: 10.1172/JCI174722. J Clin Invest. 2024. PMID: 39225099 Free PMC article.
-
New AAV9 engineered variants with enhanced neurotropism and reduced liver off-targeting in mice and marmosets.iScience. 2024 Apr 18;27(5):109777. doi: 10.1016/j.isci.2024.109777. eCollection 2024 May 17. iScience. 2024. PMID: 38711458 Free PMC article.
-
Improving retinal vascular endothelial cell tropism through rational rAAV capsid design.PLoS One. 2023 May 11;18(5):e0285370. doi: 10.1371/journal.pone.0285370. eCollection 2023. PLoS One. 2023. PMID: 37167304 Free PMC article.
-
AAV vectors: The Rubik's cube of human gene therapy.Mol Ther. 2022 Dec 7;30(12):3515-3541. doi: 10.1016/j.ymthe.2022.09.015. Epub 2022 Oct 5. Mol Ther. 2022. PMID: 36203359 Free PMC article. Review.
-
Multimodal imaging of capsid and cargo reveals differential brain targeting and liver detargeting of systemically-administered AAVs.Biomaterials. 2022 Sep;288:121701. doi: 10.1016/j.biomaterials.2022.121701. Epub 2022 Aug 6. Biomaterials. 2022. PMID: 35985893 Free PMC article.
References
-
- Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther. 2005;16:541–550. - PubMed
-
- Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004;11(Suppl 1):S10–17. - PubMed
-
- Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection. Mol Ther 2008 - PubMed
-
- Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006;14:316–327. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources